Germany· DE-A57-70f3cdce660a714e
Cysto-Gastreu S R 18
A medicinal product containing berberis vulgaris dil. d4, dulcamara dil. d4, equisetum hiemale dil. d6, eupatorium purpureum dil. d6, registered in Germany by Pharmazeutische Fabrik Dr. Reckeweg & Co. Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Berberis Vulgaris Dil. D4, Dulcamara Dil. D4, Equisetum Hiemale Dil. D6, Eupatorium Purpureum Dil. D6
- Manufacturer
- Pharmazeutische Fabrik Dr. Reckeweg & Co. Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cdefed3c-3f1b-42ab-9b68-550bf96f9a2f GET /v1/drugs/cdefed3c-3f1b-42ab-9b68-550bf96f9a2f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Berberis Vulgaris Dil. D4, Dulcamara Dil. D4, Equisetum Hiemale Dil. D6, Eupatorium Purpureum Dil. D6",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about berberis vulgaris dil. d4, dulcamara dil. d4, equisetum hiemale dil. d6, eupatorium purpureum dil. d6.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.